Myriad Genetics (MYGN) Operating Income (2009 - 2026)

Myriad Genetics (MYGN) has reported Operating Income for 18 consecutive years, with -$30.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 5.86% year-over-year to -$30.7 million; the TTM figure through Mar 2026 stood at -$388.9 million (down 212.37% YoY), while the FY2025 annual figure was -$387.2 million, down 213.52% from the prior year.
• Operating Income fell to -$30.7 million in Q1 2026 per MYGN's latest filing, from -$5.7 million in the prior quarter.
• Across five years, Operating Income topped out at -$5.7 million in Q4 2025 and bottomed at -$329.2 million in Q2 2025.
• Historically, Operating Income has averaged -$55.3 million across 5 years, with a median of -$31.4 million in 2023.
• On a YoY basis, Operating Income climbed as much as 85.38% in 2025 and fell as far as 801.92% in 2025.
• Myriad Genetics' Operating Income stood at -$52.2 million in 2022, then soared by 39.85% to -$31.4 million in 2023, then declined by 24.2% to -$39.0 million in 2024, then jumped by 85.38% to -$5.7 million in 2025, then slumped by 438.6% to -$30.7 million in 2026.
• Business Quant data shows MYGN's Operating Income at -$30.7 million in Q1 2026, -$5.7 million in Q4 2025, and -$23.3 million in Q3 2025.